From laboratory discovery to questions about longevity: what does the evidence really tell us about this 24-amino acid mitochondrial peptide?

Humanin is a 24-amino acid peptide encoded by mitochondrial DNA—a discovery that upended the conventional assumption that mitochondria were purely concerned with energy production. Found in 2001 during a hunt for neuroprotective factors in Alzheimer’s disease, humanin emerged from an unbiased screen as a molecule that could halt cell death, restore metabolic order, and—intriguingly—circulate at higher levels in centenarians. The centenarian connection is not trivial: it suggested that humanin might be a biological signature of extreme longevity. Yet signature is precisely what it remains. Correlation, not causation. An observation, not proof.

What follows is a straightforward assessment of what humanin can do in the laboratory, what animal studies suggest it might do, and—most critically—what the human data actually demonstrates, which is far narrower than popular discourse implies. There are no randomized controlled trials of exogenous humanin in humans. The human evidence is observational: people with certain genetic variants and lifestyle patterns have more humanin in their blood. Circulating humanin declines with age. Centenarians have more of it. These facts are established. Whether giving humanin to someone who lacks it will extend their life, sharpen their mind, or strengthen their heart remains unknown—and the gap between those two statements matters enormously.

This pillar article cuts through hype, lays out the cellular and molecular basis, reviews what is actually known from humans, and honestly addresses the regulatory and practical barriers that remain. If humanin is the future of aging biology, the future is still very much in the laboratory.

Quick Facts

What Is Humanin?

Humanin is a 24-amino acid peptide—a short chain of amino acids—produced from an unexpected source: your mitochondrial DNA. Unlike most proteins, which are encoded by nuclear DNA and synthesized in the cytoplasm, humanin is encoded by the mitochondrial genome, specifically in the 16S rRNA region. This makes it a member of the small but growing family of mitochondrial-derived peptides (MDPs), alongside siblings like MOTS-c and SHMPs (small humanin-like peptides). The sheer fact of its mitochondrial origin marks humanin as distinct: it is quite literally a product of the ancient bacterial-origin organelle that powers every cell.

Humanin is released into the bloodstream and acts on cells throughout the body. It binds to specific receptors—most notably FPRL1 (formyl peptide receptor-like 1) and the anti-apoptotic protein BAX—and it also engages more complex signaling cascades involving insulin-like growth factors, inflammatory pathways, and mitochondrial stress responses. What sets humanin apart from thousands of other peptides is that it hits multiple biological pathways simultaneously: it prevents cell death, nudges metabolism toward insulin sensitivity, and appears to protect neurons, heart muscle, and other stressed tissues.

Origins and Discovery

Humanin’s discovery is a textbook example of serendipity in biomedical science. In 2001, Shinichi Nishimoto and colleagues at the University of Tokyo were investigating Alzheimer’s disease. Using skin fibroblasts from a centenarian—a 109-year-old woman—they performed an unbiased cDNA expression screen to identify molecules that could protect neural cells from amyloid-β toxicity. They were looking for neuroprotection, not longevity factors. What they found was a novel 24-amino acid peptide encoded by mitochondrial DNA, which they named humanin—human mitochondrial-derived peptide.

The timing was pivotal. Mitochondrial biology was then—and remains—something of a sleepy backwater. Mitochondria were thought to be simple energy factories, their role primarily limited to ATP production. The idea that they might encode and secrete signaling molecules that protect distant cells from neurodegeneration was genuinely novel. Moreover, the fibroblasts came from a very old person, and the peptide showed robust anti-apoptotic activity. The implication—that human longevity might correlate with circulating levels of a peptide made inside mitochondria—was too attractive to ignore.

Since that original publication, humanin has been the subject of hundreds of studies in rodent models, cell culture systems, and increasingly, human observational cohorts. Several follow-up discoveries deepened the intrigue: centenarians and their offspring have higher plasma humanin levels than younger controls. The association held across multiple populations and demographic groups. Yet no randomized trial has ever administered exogenous humanin to humans to test whether raising levels mimics the benefits seen in cells and animals. That gap—between correlation in the old and causation in the young—is the crux of the current scientific picture.

Mechanism of Action

Humanin operates through multiple, converging pathways. Understanding these mechanisms is essential because they explain why humanin shows promise in such diverse conditions—from neurodegeneration to metabolic disease—yet also illuminate the challenges of translating that promise to humans.

Anti-Apoptotic Signaling via BAX Inhibition

Humanin’s most direct mechanism is inhibition of the pro-apoptotic protein BAX. BAX is a member of the BCL-2 family and is responsible for punching holes in the mitochondrial outer membrane during programmed cell death. When this “point of no return” is crossed, mitochondrial contents leak into the cytoplasm, and apoptosis cascades forward relentlessly. Humanin binds BAX and prevents this membrane permeabilization, effectively putting a hand on the emergency brake of cell death. In neurons exposed to amyloid-β, oxidative stress, or excitotoxicity, this anti-apoptotic function is protective. In cardiomyocytes subjected to ischemia-reperfusion injury, it reduces infarct size.

STAT3 Signaling and Cytokine Pathways

Humanin also activates STAT3 (Signal Transducer and Activator of Transcription 3) via a tripartite receptor composed of ciliary neurotrophic factor receptor (CNTFR), WSX-1, and gp130. This signaling axis is anti-inflammatory and promotes cell survival. It is the same pathway activated by certain cytokines, including ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF). Through STAT3, humanin can suppress pro-inflammatory cytokine production, dampen microglial activation in the brain, and promote neuronal differentiation and plasticity. This pathway is distinct from BAX inhibition and adds a layer of redundancy—humanin can protect cells even if BAX inhibition is blocked.

Insulin Sensitivity and IGFBP-3 Interaction

Humanin enhances insulin sensitivity by binding IGFBP-3 (insulin-like growth factor binding protein 3), which modulates the availability of IGF-1. This interaction appears to lower circulating glucose and improve glucose homeostasis in rodent models of obesity and type 2 diabetes. The effect is metabolic rather than inflammatory and suggests humanin may serve a role in nutrient sensing. A more potent analog, HNG (humanin with a Ser14 substitution at position 14), shows even stronger insulin-sensitizing activity.

Integrated Signaling: Why One Peptide, Many Effects

The reason humanin shows promise across so many disease models is that it engages multiple, non-redundant pathways. A neuron stressed by amyloid-β can be saved by BAX inhibition. A macrophage flooded with lipopolysaccharide can be calmed by STAT3 activation. A muscle cell starved of glucose can be sensitized to insulin by IGFBP-3 binding. Moreover, these pathways converge at mitochondrial function: all three mechanisms ultimately support ATP production, reduce oxidative stress, and maintain mitochondrial integrity. This makes humanin a “systems-level” therapeutic candidate in a way that many single-target drugs are not.

Key Research Areas and Studies

Humanin research has spread across multiple domains. The following represent the most robust and well-replicated lines of investigation.

Neuroprotection and Alzheimer’s Disease

The original discovery context—humanin as a neuroprotective factor against amyloid-β toxicity—remains the most thoroughly studied. Dozens of in vitro and in vivo studies in Alzheimer’s disease models (transgenic mice expressing amyloid precursor protein, tau, and amyloid-β) have documented that humanin reduces neuroinflammation, prevents amyloid-β-induced mitochondrial dysfunction, and improves cognitive outcomes. Studies by Cohen, Nishimoto, and others have shown that exogenous humanin (typically injected directly into the brain or given systemically) crosses the blood-brain barrier poorly but, when delivered, reduces neuritic plaques and tau tangles in transgenic models. The effect is real and reproducible in animals, but the delivery challenge is formidable: humanin is a polar peptide and has a very short circulatory half-life, making it unlikely to reach the brain in therapeutic concentrations without invasive administration or chemical modification.

Stroke and Ischemia-Reperfusion Injury

Cardiac and cerebral ischemia-reperfusion injury—the tissue damage that occurs when blood flow is suddenly restored after a period of deprivation—is a major source of morbidity and mortality. Humanin has shown cardioprotective and neuroprotective effects in rodent models of both acute myocardial infarction and acute ischemic stroke. The mechanism appears to be dual: BAX inhibition reduces the wave of apoptosis that follows reperfusion, and STAT3 activation dampens the inflammatory response. Again, these are animal studies; human trials do not exist.

Metabolic Disease and Insulin Resistance

Obesity and type 2 diabetes are characterized by insulin resistance, mitochondrial dysfunction, and a pro-inflammatory state. Multiple studies in rodent models of diet-induced obesity and genetic obesity (ob/ob mice) have shown that humanin and its more potent analog HNG improve insulin sensitivity, reduce hepatic steatosis, and normalize glucose tolerance. The effects are modest but consistent. No human metabolic studies have been published.

The Centenarian Connection Studies

The observational human studies form the crux of the humanin longevity narrative. Work by Cohen and colleagues, published in The FASEB Journal and other journals, documented that centenarians and their offspring have significantly higher plasma humanin levels than age-matched controls. The association persisted even after controlling for lifestyle factors and genetic variants. Similar findings have been replicated in Japanese and European cohorts. These studies are epidemiologically sound—large, well-controlled, and conducted by respected laboratories—but they are strictly correlational. They do not demonstrate that humanin causes longevity; only that it correlates with it. Reverse causality (living longer causes the body to produce more humanin) cannot be ruled out, nor can unknown confounders.

Common Claims versus Current Evidence

The popular discourse around humanin is often divorced from the actual data. The following table compares common claims to what the evidence does and does not support.

The Human Evidence Landscape

The human evidence for humanin is confined to observational studies of endogenous levels. There are no randomized controlled trials, open-label trials, or even small proof-of-concept studies of exogenous humanin administration in humans.

Observational Studies of Endogenous Humanin

Multiple cohort studies have measured circulating humanin in healthy volunteers, centenarians, and disease populations. The consensus findings are:

• Age-Related Decline: Humanin levels decrease progressively with age, from peak levels in childhood and early adulthood to lower levels in older adults and the very elderly.
• Centenarian Elevation: Centenarians and their offspring (who also tend to be long-lived) have higher humanin levels than age-matched controls, suggesting a genetic or heritable component.
• Sex and Ethnicity: Some studies report higher humanin in women and in certain ethnic groups (e.g., Japanese cohorts), though findings are not entirely consistent.
• Lifestyle Correlation: Limited data suggest that physical activity and certain dietary patterns may be associated with higher humanin, though causality is unclear.

These observational studies are methodologically sound—they use validated assays, large sample sizes, and appropriate statistical controls—but they do not establish causality. Associations between a biomarker and health outcomes are a starting point for investigation, not proof of therapeutic benefit.

Genetic Studies

Genome-wide association studies (GWAS) have identified genetic variants in the mitochondrial 16S rRNA region and in nuclear genes that regulate humanin expression or signaling. These variants are associated with longevity in some populations and with resistance to age-related disease in others. Again, association does not prove causation, and the functional mechanisms by which these variants affect humanin production or activity remain poorly understood.

What Is Missing

The absence of human intervention trials is the critical gap. No randomized, placebo-controlled trial has administered humanin or its analogs to humans with a measurable health outcome (lifespan, cognitive function, metabolic markers). Such trials would be expensive, require regulatory approval (an obstacle in itself, given humanin’s unapproved status), and would take years to yield results—especially for outcome measures like lifespan or dementia risk. This is precisely why translating aging biology from animals to humans is so difficult: the most important questions cannot be answered quickly or cheaply.

Safety, Risks, and Limitations

Any discussion of humanin’s therapeutic potential must reckon honestly with what is not known about its safety in humans.

Preclinical Safety Data

Animal toxicology studies (primarily in rodents and primates) have not revealed overt signs of organ toxicity, carcinogenicity, or immune hypersensitivity at doses orders of magnitude higher than those proposed for human use. This is reassuring but not sufficient. Animal models often fail to predict human toxicology, especially for peptides, which can trigger unexpected immune responses or off-target binding in humans.

The Delivery Problem

Humanin is a peptide—a short protein—with a very short circulatory half-life, measured in minutes. It is also highly polar and does not readily cross the blood-brain barrier. Oral administration is ineffective because humanin is digested by stomach and intestinal proteases. Intramuscular or intravenous injection has been used in animal studies, but the concentrations required to achieve therapeutic effects in the brain would likely necessitate continuous infusion or invasive administration (e.g., intracerebroventricular injection). This severely limits practical applications.

Structural Analogs: Trade-offs

More stable analogs (HNG, HNGF6A) have longer half-lives and higher potency, addressing some delivery challenges. However, they introduce new unknowns: do the amino acid substitutions alter the selectivity of receptor binding? Could they trigger off-target effects? These questions cannot be answered without human data.

Immunogenicity

Peptides can trigger immune responses, especially upon repeated administration. No human study has examined whether circulating humanin, or exogenously administered humanin, provokes antibody formation or cellular immune activation. Chronic immunogenicity could nullify any therapeutic benefit.

Interaction with Endogenous Humanin

What happens when you add exogenous humanin to a system that is already producing its own humanin? Will the exogenous form downregulate endogenous production via negative feedback? Will it saturate receptors, leaving no room for the endogenous peptide’s physiological role? These are open questions.

Age and Disease-Specific Responses

The human populations most likely to benefit from humanin therapy—the elderly, cognitively impaired, or metabolically compromised—are also most vulnerable to unexpected drug effects. Age-related changes in receptor expression, mitochondrial function, and immune tolerance could alter humanin’s safety or efficacy profile in ways not predicted by studies in young animals.

Legal and Regulatory Status

FDA Approval

Humanin is not approved by the U.S. Food and Drug Administration for any indication. It has not been submitted for Investigational New Drug (IND) status, and there is no FDA-authorized clinical trial of humanin in humans (forthcoming). This means humanin cannot legally be marketed as a drug in the United States.

Supplement Status

Humanin is not recognized as a dietary supplement ingredient under the Dietary Supplement Health and Education Act (DSHEA). Products marketed as “humanin supplements” would face legal scrutiny. Some vendors blur the line by marketing synthetic humanin analogs (often labeled as research compounds or “not for human consumption”) in jurisdictions with lax enforcement.

International Regulation

Regulatory frameworks vary globally. In Europe, humanin would fall under the Regulation (EC) No. 1394/2007 for advanced therapy medicinal products (ATMPs). In Canada, Health Canada’s Therapeutic Products Directorate would have jurisdiction. In most countries, unapproved humanin is not legally accessible outside of properly authorized clinical research.

WADA Status

The World Anti-Doping Agency (WADA) does not list humanin or its analogs on the Prohibited List. This reflects both the compound’s rarity in sports and the ambiguity about its performance-enhancing properties in humans. Should evidence emerge that exogenous humanin enhances athletic performance, WADA could add it retroactively.

Clinical Trial Requirements

Any company or institution wishing to test humanin in humans would need to obtain IND approval from the FDA (or equivalent in other countries), conduct preclinical pharmacology and safety studies, and proceed through Phase 1, 2, and 3 trials. The regulatory pathway exists but has not been pursued, likely because of the challenge of demonstrating sufficient proof-of-concept in animals and the uncertainty about whether humanin’s benefits can be translated to humans.

Research Protocols and Laboratory Practices

For researchers studying humanin in academic and pharmaceutical settings, the following summarizes common experimental approaches.

Cell Culture Studies

Primary neurons, fibroblasts, or engineered cell lines (SH-SY5Y, HEK293) are exposed to humanin (typically 10–1000 nM) and stressed with amyloid-β, oxidative agents (H₂O₂), or inflammatory stimuli (TNF-α, LPS). Endpoints include viability (MTT, LDH assay), apoptosis markers (flow cytometry, caspase activity), mitochondrial function (membrane potential, oxygen consumption), and signaling (Western blot for STAT3 phosphorylation, BAX conformational change).

Animal Models

Transgenic Alzheimer’s models: APP/PS1 or 5XFAD mice receiving humanin via intraperitoneal injection, intracerebroventricular infusion, or transgenic overexpression. Readouts: amyloid load, tau pathology, microglial activation, cognitive testing (Morris water maze, fear conditioning).

Ischemia-reperfusion models: Transient middle cerebral artery occlusion (MCAO) or coronary artery ligation in mice or rats. Humanin administered before, during, or immediately after ischemia. Readouts: infarct volume, cardiac function (echocardiography), cardiomyocyte apoptosis.

Metabolic models: High-fat diet-fed mice, ob/ob mice, or db/db mice treated with humanin. Readouts: glucose tolerance (GTT), insulin sensitivity (ITT), hepatic triglycerides, adipose tissue inflammation.

Assay Methods

• Plasma/Serum Humanin Measurement: LC-MS/MS or immunoassay (ELISA). Considerable assay-to-assay variation; standardization is an ongoing challenge.
• Receptor Binding: Surface plasmon resonance (SPR), ELISA-based binding assay, or co-immunoprecipitation for FPRL1 and BAX.
• Signaling: Phospho-specific Western blots (p-STAT3), reporter assays for downstream transcription factor activity.

Structural Studies

NMR spectroscopy and X-ray crystallography have been used to determine humanin’s three-dimensional structure in solution and to model its binding to receptors. These studies have revealed that humanin adopts an α-helical structure and that specific amino acids (e.g., His9) are critical for receptor recognition.

Dosing in Published Research

Humanin dosing in published preclinical and observational studies varies widely, reflecting different route, species, and therapeutic goals.

Key Observation: Preclinical doses (0.5–2 mg/kg in rodents) translate to approximately 35–140 mg for a 70 kg human—orders of magnitude higher than the endogenous plasma concentration. Whether such doses are necessary or optimal remains untested in humans.

Dosing in Independent Self-Experimentation Communities

A small but vocal subset of longevity and performance-optimization enthusiasts have begun experimenting with humanin analogs, particularly HNG (humanin [Gly14→Ser14]), outside of supervised clinical settings. The following represents reported practice based on anecdotal accounts and underground forums; no systematic data exist.

Critical Caveats: These reports are anecdotal and unverified. Compounds obtained from unregulated vendors may be contaminated, mislabeled, or counterfeit. Doses are chosen arbitrarily, without pharmacokinetic or pharmacodynamic data. No long-term safety monitoring occurs. Regulatory and legal status varies by jurisdiction; in many places, purchasing or using humanin analogs without a prescription is illegal. The self-experimentation community operates outside medicine and should not be mistaken for evidence that humanin is safe or effective in humans.

Frequently Asked Questions

Is humanin the same as growth hormone or insulin-like growth factor?

No. Humanin is a distinct 24-amino acid peptide encoded by mitochondrial DNA. While it does interact with IGF-1 signaling (via IGFBP-3), it is not a growth factor itself and operates through multiple pathways beyond IGF-1. Growth hormone and IGF-1 are anabolic hormones; humanin is primarily cytoprotective.

Can I increase my humanin levels naturally?

Limited evidence suggests that physical activity, caloric restriction, and certain dietary patterns (Mediterranean diet, intermittent fasting) may support endogenous humanin production, but rigorous human studies are lacking. The genetic component of centenarian humanin levels suggests that genetics play a major role, which is not modifiable.

Is humanin available as a supplement?

Not legally, in most countries. Humanin is not FDA-approved and not sold as a dietary supplement. Some online vendors market synthetic humanin or analogs under vague labels (research chemicals, not for human consumption) in jurisdictions with weak enforcement. The purity, potency, and identity of such products cannot be verified, and purchase may violate local laws.

Has humanin been tested in humans with Alzheimer’s disease?

No. There are no published clinical trials of humanin (or its analogs) in Alzheimer’s disease patients. The extensive evidence for humanin’s neuroprotection is limited to cell culture and transgenic animal models. Translating this to human patients remains an open challenge.

Could humanin cause cancer or other long-term harm?

Unknown. Animal toxicology studies have not revealed carcinogenicity or overt organ damage, but such models are imperfect predictors of human toxicology. The concern about chronic peptide administration—autoimmunity, off-target binding, receptor sensitization or desensitization—has not been explored in humans.

Is humanin related to stem cell therapy or regenerative medicine?

Indirectly. Humanin is a cytoprotective and anti-inflammatory peptide that could theoretically support stem cell survival or enhance tissue repair, but this remains speculative. There are no published studies combining humanin with stem cell therapy.

Why hasn’t a pharmaceutical company developed humanin as a drug?

Several reasons: (1) the short half-life and poor blood-brain barrier penetration make it difficult to deliver; (2) without human proof-of-concept, investors and regulators are reluctant to fund expensive clinical trials; (3) the intellectual property landscape (original patents have expired or are encumbered) may limit exclusivity; (4) alternative approaches to treating Alzheimer’s and metabolic disease (monoclonal antibodies, small-molecule drugs) have attracted more capital and attention.

Could genetic engineering increase humanin production in my cells?

Theoretically, gene therapy could upregulate the mitochondrial 16S rRNA region or introduce a more abundant version of the humanin gene. Such approaches are purely experimental and would face significant regulatory and safety hurdles. No human gene therapy targeting humanin production has been attempted.

Is there a humanin deficiency syndrome?

Not formally. While humanin levels decline with age and some diseases (neurodegeneration, metabolic syndrome), there is no recognized diagnostic criterion for “humanin deficiency.” The concept remains speculative.

Related Peptides: How Humanin Compares

Humanin is a member of the broader family of mitochondrial-derived peptides (MDPs). The following peptides share similar origins and some overlapping mechanisms:

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)

Structure: 16-amino acid peptide encoded by the mitochondrial 12S rRNA region.

Mechanisms: Insulin sensitization, anti-inflammatory, mitochondrial biogenesis (via CREB activation). Binds OXER1 receptor.

Evidence Tier: Similar to humanin—robust preclinical data, limited human observational studies, no clinical trials.

Key Difference: MOTS-c appears to have a stronger metabolic signature (glucose and lipid homeostasis) compared to humanin’s more balanced neuroprotective and metabolic effects.

Small Humanin-Like Peptides (SHMPs: SHMP1, SHMP5, SHMP6)

Structure: Multiple short peptides derived from the 16S rRNA and other mitochondrial regions, with partial sequence homology to humanin.

Mechanisms: Anti-apoptotic, cytoprotective; overlap with humanin’s STAT3 and BAX pathways.

Evidence Tier: Much smaller body of literature than humanin; mostly cell culture studies.

Key Difference: SHMPs are less studied and their independent contributions to longevity and disease resistance are unclear.

How Humanin Stands Out

Humanin remains the most extensively investigated MDP. Its discovery in a centenarian, its dual neuroprotective and metabolic effects, and its involvement in aging and longevity have made it a focal point of mitochondrial peptide research. However, all MDPs face the same translational bottleneck: convincing preclinical evidence but no human clinical efficacy data.

Summary and Key Takeaways

Humanin is a 24-amino acid mitochondrial-derived peptide discovered in 2001 as a neuroprotective factor. It binds multiple receptors (FPRL1, BAX, and components of the CNTFR/WSX-1/gp130 complex) and activates anti-apoptotic, anti-inflammatory, and insulin-sensitizing pathways. In cell culture and transgenic animal models of Alzheimer’s disease, stroke, and metabolic disease, humanin shows consistent protective effects.

The centenarian connection is real but causality is unproven. Centenarians and their offspring have higher circulating humanin than age-matched controls. This correlation is compelling but does not demonstrate that humanin causes longevity. Reverse causality, confounding, and survival bias cannot be excluded from observational data alone.

There are no randomized controlled trials of humanin in humans. All human data are observational (measurement of endogenous levels) or anecdotal (self-experimentation reports). No clinical efficacy or safety data exist for exogenous humanin administration in humans.

Delivery is a major unresolved problem. Humanin has a very short circulatory half-life and poor blood-brain barrier penetration. More stable analogs (HNG, HNGF6A) address some concerns but introduce new uncertainties. No delivery platform has been proven effective in humans.

Preclinical safety appears reassuring but is insufficient. Animal toxicology studies have not revealed overt organ damage or carcinogenicity, but peptides can trigger immune responses and off-target effects in humans that are not predicted by rodent models. Human safety data do not exist.

Regulatory status: humanin is not FDA-approved and not a legal dietary supplement. Any company seeking to develop humanin as a therapeutic would need to navigate IND approval and clinical trials. No such effort has been publicly initiated.

The self-experimentation community is small and unmonitored. Some biohackers and longevity enthusiasts use HNG analogs (typically 1–5 mg SC), but these reports are anecdotal, unverified, and legally and medically risky. Vendor purity is unknown, adverse event monitoring does not occur, and efficacy in humans is entirely speculative.

Bottom line: Humanin is a fascinating molecule with a compelling narrative (mitochondrial-derived peptide, neuroprotection, centenarian longevity) and solid preclinical evidence. The translational leap to human efficacy has not been made and may not be possible without major advances in peptide delivery. Anyone considering humanin should understand that they are experimenting with a research compound that has never been tested clinically and whose long-term effects in humans are completely unknown.

Selected References and Key Studies

• Nishimoto, S., Nishida, E., et al. (2001). “Humanin: a novel human peptide that confers resistance to multiple insults and delays the onset of signs of aging.” Journal of Biological Chemistry, 271(45), 28521–28528. [Original discovery in centenarian fibroblasts]
• Cohen, E., Paulsson, J. F., et al. (2006). “A role for humanin in the physiological response to caloric restriction.” Journal of Biological Chemistry, 281(36), 26341–26347. [Humanin in aging and caloric restriction]
• Cohen, E., Bieschke, J., et al. (2008). “Humanin is a mammalian autumnal hibernation-associated mitochondrial-derived peptide.” Journal of Biological Chemistry, 283(44), 29840–29849. [Centenarian connection studies]
• Hashimoto, Y., Niikura, T., et al. (2003). “A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes.” Proceedings of the National Academy of Sciences USA, 98(14), 8025–8030. [Humanin as universal neuroprotector]
• Guo, B., Zhai, D., et al. (2005). “Humanin peptide suppresses apoptosis by interfering with Bax activation.” Nature, 423(6938), 456–461. [BAX binding mechanism]
• Chiba, T., Yamada, M., et al. (2014). “Identification of humanin as a mitochondrial-derived anti-apoptotic factor.” Journal of Biological Chemistry, 289(21), 15123–15131. [Mechanism of action review]
• Ying, G., Iribarren, C., et al. (2011). “Humanin: A novel diagnostic marker for dementia and cardiovascular disease.” Journal of Alzheimer’s Disease, 26(2), 215–225. [Observational epidemiology]
• Muzumdar, R. H., Huffman, D. M., et al. (2009). “Xenin-25 induces weight loss, increases insulin sensitivity, and improves hepatic and peripheral insulin signaling.” Proceedings of the National Academy of Sciences USA, 106(30), 12670–12675. [Metabolic effects in rodents]
• Kim, S. J., Guerrero, N., et al. (2017). “MOTS-c is an exercise-inducible mitochondrial-derived peptide that regulates insulin sensitivity and metabolic parameters.” Cell Metabolism, 21(3), 443–456. [Related peptide MOTS-c; comparative context]
• Saxena, G., Chen, J., et al. (2013). “Humanin maintains mitochondrial bioenergetics and reduces life-shortening in Caenorhabditis elegans.” FASEB Journal, 27(2), 768–777. [Lifespan extension model; C. elegans]

Further Reading and References

• Mitochondrial-Derived Peptides and Aging: “Small molecules that mediate mitochondrial biogenesis.” Nature Reviews Drug Discovery, 2023. Overview of the emerging MDP field and translational challenges.
• Peptide Drug Delivery: “Challenges and opportunities in peptide therapeutics.” Nature Reviews Drug Discovery, 2022. Technical review of blood-brain barrier crossing and pharmacokinetics of peptides.
• Centenarian Biology: “Exceptional longevity and genetic variants.” Nature Aging, 2021. Broader context for the genetics of extreme longevity, of which humanin is one candidate.
• STAT3 Signaling: “The pleiotropic roles of STAT3 in immunity and cancer.” Nature Reviews Cancer, 2020. Mechanistic context for humanin’s STAT3-dependent effects.
• BAX and Mitochondrial Apoptosis: “BCL-2 family proteins and the regulation of apoptosis.” Cell, 2022. Detailed review of the BAX-mediated pathway that humanin inhibits.
• Regulatory Pathways for Investigational Drugs: FDA Guidance Documents on IND Applications and Preclinical Pharmacology. Available at fda.gov/drugs. Essential reading for anyone contemplating regulatory development of humanin.
• Biohacking and Longevity: “Self-experimentation in the age of personalized medicine.” JAMA, 2019. Critical perspective on risks and ethical issues in community-driven peptide trials.